晚期胰腺癌的分子治疗研究现状  

Research status of molecular therapy for advanced pancreatic cancer

作　　者：王丹[1] 范晓娜 黎清炜 李志伟[1] WANG Dan;FAN Xiaona;LI Qingwei;LI Zhiwei(Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院消化内科,黑龙江哈尔滨150001

出　　处：《现代肿瘤医学》2022年第6期1108-1112,共5页Journal of Modern Oncology

摘　　要：胰腺癌是全球第七大致命的恶性肿瘤,分别是美国胃肠道恶性肿瘤和癌症相关死亡的第二大和第三大原因。与其他恶性肿瘤相比,晚期胰腺癌患者的生存率最低,中位总体生存率为2~8个月,5年生存率为8.5%。治疗十分困难,给临床医生带来极大挑战。目前晚期胰腺癌的治疗药物匮乏,化疗仍然是其主要治疗方法。虽然化疗能短暂的控制疾病的进展,但是在生存期的延长方面却差强人意。分子靶向治疗已在其他的瘤种中取得了里程碑般的成就,譬如肺癌、结直肠癌等,但晚期胰腺癌患者的分子靶向治疗效果并不显著。这需要我们去寻找新的治疗靶点和药物。本文基于胰腺癌信号传导通路及肿瘤微环境,总结和分析晚期胰腺癌分子治疗的研究现状,探索未来胰腺癌治疗的发展方向。Pancreatic cancer(PDAC)is the seventh most deadly malignancy worldwide.It is the second and third leading cause of gastrointestinal malignancies and cancer-related deaths,respectively,in the US.Compared to other malignancies,advanced PDAC has the lowest survival rate,with a median overall survival of 2~8 months and a 5-year survival of 8.5%.The treatment of pancreatic cancer is very difficult,which brings great challenges to clinicians.At present,the treatment of advanced pancreatic cancer is scarce,and chemotherapy is still the main treatment method.Although chemotherapy can temporarily control the progress of the disease,it is unsatisfactory in terms of prolonged survival.Molecular targeted therapy has achieved milestone achievements in other tumor types,such as lung cancer,colorectal cancer,etc,but molecular targeted therapy in patients with advanced pancreatic cancer has not achieved significant results.This requires us to find new therapeutic targets and drugs.Based on the signal transduction pathway and tumor microenvironment of pancreatic cancer,this article summarizes and analyzes the research status of molecular therapy for advanced pancreatic cancer,and explores the development direction of future pancreatic cancer treatment.

关 键 词：胰腺癌 靶向治疗 免疫治疗 肿瘤疫苗 肿瘤干细胞 肿瘤基质 肿瘤间质 

分 类 号：R735.9[医药卫生—肿瘤]